Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin E Gleave

Showing results (11-20 of 325) with videos related to

Pageof 33
Sort By:
Nature Reviews. Cancer|May 21, 2005
Antisense therapy for cancerMartin E Gleave, Brett P Monia
Histopathology|January 4, 2012
Targeted therapy in prostate cancerNiall M Corcoran, Martin E Gleave
European Urology|October 23, 2010
Words of wisdom. Re: comparative effectiveness of minimally invasive versus open radical prostatectomyAnthony J Koupparis, Martin E Gleave
Translational Andrology and Urology|January 28, 2016
Novel non-AR therapeutic targets in castrate resistant prostate cancerPaul J Toren, Martin E Gleave
The Canadian Journal of Urology|January 6, 2004
Prostate specific antigen: an updated reviewAlan So, Larry Goldenberg, Martin E Gleave
International Journal of Urology : Official Journal of the Japanese Urological Association|October 6, 2005
Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinicHideaki Miyake, Isao Hara, Martin E Gleave
The Urologic Clinics of North America|October 23, 2012
Targeted therapies in metastatic castration-resistant prostate cancer: beyond the androgen receptorYohann Loriot, Amina Zoubeidi, Martin E Gleave
Expert Opinion on Investigational Drugs|November 18, 2008
Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancerKim N Chi, Amina Zoubeidi, Martin E Gleave
Nature Reviews. Urology|October 9, 2019
Towards precision oncology in advanced prostate cancerSheng-Yu Ku, Martin E Gleave, Himisha Beltran
The Canadian Journal of Urology|March 1, 1996
Urinary bladder endocervicosis: a case report and review of the literatureEdward C. Jones, Martin E. Gleave, Charalambos Andreou
Pageof 33

Showing results (11-20 of 325) with videos related to

Sort By:
Pageof 33
Nature Reviews. Cancer|May 21, 2005
Antisense therapy for cancerMartin E Gleave, Brett P Monia
Histopathology|January 4, 2012
Targeted therapy in prostate cancerNiall M Corcoran, Martin E Gleave
European Urology|October 23, 2010
Words of wisdom. Re: comparative effectiveness of minimally invasive versus open radical prostatectomyAnthony J Koupparis, Martin E Gleave
Translational Andrology and Urology|January 28, 2016
Novel non-AR therapeutic targets in castrate resistant prostate cancerPaul J Toren, Martin E Gleave
The Canadian Journal of Urology|January 6, 2004
Prostate specific antigen: an updated reviewAlan So, Larry Goldenberg, Martin E Gleave
International Journal of Urology : Official Journal of the Japanese Urological Association|October 6, 2005
Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinicHideaki Miyake, Isao Hara, Martin E Gleave
The Urologic Clinics of North America|October 23, 2012
Targeted therapies in metastatic castration-resistant prostate cancer: beyond the androgen receptorYohann Loriot, Amina Zoubeidi, Martin E Gleave
Expert Opinion on Investigational Drugs|November 18, 2008
Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancerKim N Chi, Amina Zoubeidi, Martin E Gleave
Nature Reviews. Urology|October 9, 2019
Towards precision oncology in advanced prostate cancerSheng-Yu Ku, Martin E Gleave, Himisha Beltran
The Canadian Journal of Urology|March 1, 1996
Urinary bladder endocervicosis: a case report and review of the literatureEdward C. Jones, Martin E. Gleave, Charalambos Andreou
Pageof 33